NKCL
Bio Group, a brand specializing in ‘Personalized Immune Care’, held ‘The 1st
Thanks Day’ festival at the Grand Hyatt Seoul Grand Ballroom on the 22nd.
NKCL
Bio Group, a bio company that researches and develops NK immune cell therapy,
has patents and original technology for NK cell culture medium addition kit and
culture method. ‘NK cells’ are immune cells in the body that have the ability
to kill abnormal cells, and are effective in eliminating cancer cells and
anti-aging.
In
the presentation of '2022 NKCL Innovation Strategy and the Future', CEO Yoon
Ji-hyun said, "Microsoft founder Bill Gates mentioned that the three
things that will change the world are immuno-oncology drugs, the microbiome,
and the treatment for dementia.", mentioning the promise of
immuno-oncology and microbiome technology that NKCL Bio Group is focussed on.
The global immuno-oncology drugs market is expected to grow 17% annually from
2017, and reach approximately $103.4 bn in 2024 taking 44% of the total
anticancer drug market($233 bn).(source: GBI Research).
In
addition, with the completion of an Automated Immune Cell Culture platform
based on artificial intelligence in February, she emphasized that “By enabling
mass-produced and popularized immune cell therapy optimized for each
individual, more people, including terminal cancer patients, can take the NK
immune cell therapy.”
“We
anticipate, declare, and move forward that the standards we set will become the
world's standard in the immune market in the future. For the healthy aging of
the global population, by the Automated Cull Culture system designed to meet
GMP certifications-all KGMP/EUGMP/cGMP”said the CEO expressing the anticipation
for the ripple effect of NKCL Bio Group's Automated Culture System in the
global immuno-oncology market.
Existing
production of immune cell therapies relies on specialized researchers for the
entire process of customized culture, so there was a barrier to entry due to
high prices. NKCL Bio Group's automatic culture system is expected to
dramatically lower the cost of the existing expensive immune cell therapy by
improving productivity by more than 100 times compared to the existing manual
production method.
Shin
Dong-hwa, chairman of NKCL Bio Group, said, “When everyone says it’s
impossible, NKCL has made a creative idea into realization and achieved an ‘NK
cell culture automation system’ with own original technology. In this era of
virus outbreak, for modern people who suffers from cancer with a chance of 1/3,
we, NKCL Bio Group, will take responsibility for human health with more
advanced treatments and systems.” He also said, “In the future, beyond Korea,
we will grow into a world-class company leading the global biopharmaceutical
market worth about 330 trillion won as of 2020.”
The
1st Thanks Day event was an online and offline hybrid event that invites about
300 VIPs and partners and implements simultaneously a zoom live system and
YouTube real-time streaming that can accommodate about 3,000 people. At the end
of the event, where the atmosphere was heightened by singer Sohyang's
performance, MC, the Professor Kim Chang-ok, gave a special mini-lecture for
the NKCL Bio Group, receiving evaluations of suggesting a new paradigm for the
existing corporate events.
In
addition, a total of 500 million won worth of Lucky Draws were held for online
and offline participants, intriguing many people in various ways.
Meanwhile,
NKCL Bio Group provides personalized immune checkup and treatment programs
through cooperation with Dongtan's "NK Immune Therapy Center (NK Dongtan
Clinic)." The NK Immune Therapy Center is a comprehensive medical flex
mall, consists of an Immune Therapy Center, an Immune Checkup Center, an Immune
Drustore, and an immun cafe.